Artivion (NYSE:AORT) Insider John Davis Sells 3,773 Shares

Artivion, Inc. (NYSE:AORT) insider John Davis sold 3,773 shares of Artivion stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $37.59, for a total value of $141,827.07. Following the transaction, the insider owned 190,943 shares of the company’s stock, valued at $7,177,547.37. The trade was a 1.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Artivion Stock Performance

NYSE:AORT traded up $0.31 on Wednesday, hitting $35.66. The company’s stock had a trading volume of 300,261 shares, compared to its average volume of 399,410. Artivion, Inc. has a one year low of $21.97 and a one year high of $48.25. The firm has a market capitalization of $1.71 billion, a P/E ratio of 178.32 and a beta of 1.59. The stock has a fifty day moving average of $42.51 and a two-hundred day moving average of $43.14. The company has a current ratio of 3.53, a quick ratio of 2.62 and a debt-to-equity ratio of 0.49.

Artivion (NYSE:AORT) last posted its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The business had revenue of $118.30 million for the quarter, compared to analyst estimates of $116.42 million. Artivion’s revenue was up 19.2% compared to the same quarter last year. Research analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Needham & Company LLC reissued a “buy” rating and issued a $58.00 price target on shares of Artivion in a report on Monday, February 2nd. Oppenheimer restated an “outperform” rating and set a $50.00 price objective on shares of Artivion in a report on Friday, November 7th. Canaccord Genuity Group decreased their target price on Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Finally, Citizens Jmp increased their target price on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $48.97.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in AORT. Aster Capital Management DIFC Ltd raised its position in shares of Artivion by 402.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after buying an additional 519 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Artivion in the third quarter valued at approximately $27,000. Larson Financial Group LLC increased its stake in Artivion by 148.5% during the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after acquiring an additional 563 shares during the period. USA Financial Formulas increased its stake in Artivion by 163.5% during the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after acquiring an additional 703 shares during the period. Finally, Smartleaf Asset Management LLC raised its holdings in Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after acquiring an additional 538 shares in the last quarter. 86.37% of the stock is owned by institutional investors.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.